Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73

被引:37
作者
Bensaad, K
Le Bras, M
Unsal, K
Strano, S
Blandino, G
Tominaga, O
Rouillard, D
Soussi, T
机构
[1] Inst Curie, Lab Genotoxicol Tumeurs, F-75005 Paris, France
[2] Inst Curie, Serv Cytometrie, F-75005 Paris, France
[3] Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy
关键词
D O I
10.1074/jbc.M208233200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Xenopus p53 has biological and biochemical properties similar to those of human p53, except for optimal temperature. The frog protein is fully active at 30 degreesC and inactive at 37 degreesC, leading to a temperature-sensitive behavior similar to that of the human mutant p53Ala(143) and the murine mutant p53Val(135). Using hybrid proteins between human and Xenopus expressed from artificial p53 minigenes, we have been able to demonstrate that change of conformation of the DNA-binding domain is the major determinant of this heat sensitivity. It as been reported that some human tumor-derived p53 mutants can engage in a physical association with p73, thus inhibiting its transactivating properties. The mechanism of this association remains to be elucidated. The nature of the mutant p53 that can engage in this association also remains controversial. Using the unique opportunity of the temperature sensitivity of Xenopus p53, we demonstrate that binding of, and interference with p73 require a change of conformation in the p53 protein. This interaction occurs through the DNA-binding domain of p53 only when it is in a denatured state. These results reinforce the notion that mutant p53 with a conformational change can act as a down-regulator of the p73 pathway in human cancer and could confer a selective advantage to the tumor.
引用
收藏
页码:10546 / 10555
页数:10
相关论文
共 44 条
[1]  
Agami R, 1999, NATURE, V399, P809
[2]   Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy [J].
Bullock, AN ;
Henckel, J ;
Fersht, AR .
ONCOGENE, 2000, 19 (10) :1245-1256
[3]   Prediction of complete gene structures in human genomic DNA [J].
Burge, C ;
Karlin, S .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 268 (01) :78-94
[4]   CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS [J].
CHO, YJ ;
GORINA, S ;
JEFFREY, PD ;
PAVLETICH, NP .
SCIENCE, 1994, 265 (5170) :346-355
[5]   p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53 [J].
Davison, TS ;
Vagner, C ;
Kaghad, M ;
Ayed, A ;
Caput, D ;
Arrowsmith, CH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (26) :18709-18714
[6]  
Di Como CJ, 1999, MOL CELL BIOL, V19, P1438
[7]   DEFINITION OF A CONSENSUS BINDING-SITE FOR P53 [J].
ELDEIRY, WS ;
KERN, SE ;
PIETENPOL, JA ;
KINZLER, KW ;
VOGELSTEIN, B .
NATURE GENETICS, 1992, 1 (01) :45-49
[8]   p63 and p73 are required for p53-dependent apoptosis in response to DNA damage [J].
Flores, ER ;
Tsai, KY ;
Crowley, D ;
Sengupta, S ;
Yang, A ;
McKeon, F ;
Jacks, T .
NATURE, 2002, 416 (6880) :560-564
[9]   A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain [J].
Gaiddon, C ;
Lokshin, M ;
Ahn, J ;
Zhang, T ;
Prives, C .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (05) :1874-1887
[10]   ACTIVATING MUTATIONS IN P53 PRODUCE A COMMON CONFORMATIONAL EFFECT - A MONOCLONAL-ANTIBODY SPECIFIC FOR THE MUTANT FORM [J].
GANNON, JV ;
GREAVES, R ;
IGGO, R ;
LANE, DP .
EMBO JOURNAL, 1990, 9 (05) :1595-1602